Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Massarelli, V. Miller, N. Leighl, P. Rosen, K. Albain, L. Hart, O. Melnyk, L. Sternås, J. Ackerman, R. Herbst (2007)
Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)Journal of Clinical Oncology, 25
M. Chiron, P. Vrignaud, P. Lejeune, B. Demers, W. Leopold, M. Bissery (2007)
Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor modelsMolecular Cancer Therapeutics, 6
A. Tarhini, S. Christensen, P. Frankel, K. Margolin, C. Ruel, J. Shipe-Spotloe, M. Demark, J. Kirkwood (2009)
Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
Y. Piao, J. Heymach, B. Bekele, K. Camphausen, P. Wen, J. Liu, W. Yung, J. Groot (2016)
Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
C. Karapetis, S. Khambata-Ford, D. Jonker, C. O'Callaghan, D. Tu, N. Tebbutt, R. Simes, H. Chalchal, J. Shapiro, S. Robitaille, T. Price, L. Shepherd, H. Au, C. Langer, M. Moore, J. Zalcberg (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.The New England journal of medicine, 359 17
E. Cutsem, D. Khayat, C. Verslype, B. Billemont, S. Tejpar, J. Méric, K. Soussan-Lazard, S. Assadourian, S. Cartot-Cotton, O. Rixe (2013)
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.European journal of cancer, 49 1
J. Tabernero, C. Allegra, P. Rougier, G. Scagliotti, P. Philip, R. Lakomy, R. Ramlau, S. Assadourian, Soazig Chevalier, E. Cutsem (2012)
Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl)Journal of Clinical Oncology, 30
X. Le, Weiqun Mao, Chunhua Lu, Angela Thornton, J. Heymach, A. Sood, Robert Jr. (2008)
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2Cell Cycle, 7
S. Cascinu, M. Staccioli, G. Gasparini, P. Giordani, V. Catalano, R. Ghiselli, C. Rossi, A. Baldelli, F. Graziano, V. Saba, P. Muretto, G. Catalano (2000)
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 7
Yutaka Takahashi, S. Tucker, Y. Kitadai, A. Koura, C. Bucana, K. Cleary, L. Ellis (1997)
Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.Archives of surgery, 132 5
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
M. Papetti, I. Herman (2002)
Mechanisms of normal and tumor-derived angiogenesis.American journal of physiology. Cell physiology, 282 5
R. Ramlau, V. Gorbunova, T. Ciuleanu, S. Novello, M. Ozguroglu, T. Goksel, C. Baldotto, J. Bennouna, F. Shepherd, Solenn Le-Guennec, A. Rey, Vincent Miller, N. Thatcher, G. Scagliotti (2012)
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 29
C. Allegra, J. Tabernero, P. Rougier, G. Scagliotti, P. Philip, R. Lakomy, R. Ramlau, S. Assadourian, Soazig Chevalier, E. Cutsem (2012)
Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4_suppl
I. Tannock, K. Fizazi, S. Ivanov, C. Karlsson, A. Flechon, I. Skoneczna, F. Orlandi, G. Gravis, V. Matveev, S. Bavbek, T. Gil, L. Viana, O. Aren, O. Karyakin, T. Elliott, A. Birtle, E. Magherini, L. Hatteville, D. Petrylak, B. Tombal, M. Rosenthal (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.The Lancet. Oncology, 14 8
R. Galiano, Oren Tepper, Catherine Pelo, Kirit Bhatt, M. Callaghan, N. Bastidas, S. Bunting, Hope Steinmetz, G. Gurtner (2004)
Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells.The American journal of pathology, 164 6
W. Tew, N. Colombo, I. Ray-Coquard, A. Oza, J. Campo, G. Scambia, D. Spriggs (2007)
VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II studyJournal of Clinical Oncology, 25
A. Gaya, Vivien Tse (2012)
A preclinical and clinical review of aflibercept for the management of cancer.Cancer treatment reviews, 38 5
E. Sherman, A. Ho, S. Haque, R. Ghossein, D. Lisa, H. Schöder, M. Baum, A. Shaha, R. Tuttle, D. Pfister (2010)
A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma.Journal of Clinical Oncology, 28
(2008)
Combination of the antiangiogenic agent aflibercept results in greater antitumor activity. In: Proceedings from the 99th American association for cancer research annual meeting
C. Fischer, B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, Lucia Pattarini, E. Chorianopoulos, L. Liesenborghs, Marta Koch, M. Mol, M. Autiero, S. Wyns, S. Plaisance, L. Moons, N. Rooijen, M. Giacca, J. Stassen, M. Dewerchin, D. Collen, P. Carmeliet (2007)
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy VesselsCell, 131
F. Baffert, T. Le, B. Sennino, G. Thurston, C. Kuo, D. Hu-Lowe, D. McDonald (2006)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.American journal of physiology. Heart and circulatory physiology, 290 2
P. Twardowski, W. Stadler, P. Frankel, P. Lara, C. Ruel, G. Chatta, E. Heath, D. Quinn, D. Gandara (2010)
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.Urology, 76 4
E. Cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausová, T. Macarulla, P. Ruff, G. Hazel, V. Moiseyenko, D. Ferry, J. Mckendrick, J. Polikoff, A. Tellier, R. Castan, C. Allegra (2012)
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
C. Pericay, G. Folprecht, M. Saunders, Anne Thomas, J. Roh, R. López, T. Höhler, Jun Kim, C. Zilocchi, E. Boëlle, J. Zalcberg (2012)
O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM)Annals of Oncology, 23
Limin Hu, J. Hofmann, J. Holash, G. Yancopoulos, A. Sood, R. Jaffe (2005)
Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer ModelClinical Cancer Research, 11
J. Holash, S. Davis, N. Papadopoulos, S. Croll, L. Ho, M. Russell, P. Boland, Raymond Leidich, D. Hylton, E. Burova, E. Ioffe, Tammy Huang, C. Radziejewski, Kevin Bailey, J. Fandl, T. Daly, S. Wiegand, G. Yancopoulos, J. Rudge (2002)
VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences of the United States of America, 99
A. Lockhart, M. Rothenberg, J. Dupont, W. Cooper, P. Chevalier, L. Sternås, G. Buzenet, E. Koehler, J. Sosman, L. Schwartz, D. Gultekin, J. Koutcher, E. Donnelly, R. Andal, I. Dancy, D. Spriggs, W. Tew (2010)
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 2
D. Hicklin, L. Ellis (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 5
J. Groot, Y. Piao, H. Tran, M. Gilbert, Hua-kang Wu, Jun Liu, B. Bekele, T. Cloughesy, M. Mehta, H. Robins, A. Lassman, L. Deangelis, K. Camphausen, A. Chen, W. Yung, M. Prados, P. Wen, J. Heymach (2011)
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with AfliberceptClinical Cancer Research, 17
N. Isambert, G. Freyer, S. Zanetta, B. You, P. Fumoleau, C. Falandry, L. Favier, S. Assadourian, K. Soussan-Lazard, S. Ziti-Ljajic, V. Trillet‐Lenoir (2012)
Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid TumorsClinical Cancer Research, 18
A. Ceschia (2010)
12th World Congress on Gastrointestinal Cancer.The Lancet. Oncology, 11 8
S. Limentani, R. Just, A. Purdham, M. Mulay, A. Bair, J. Tamby, L. Chap, L. Rosen (2008)
A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary resultsJournal of Clinical Oncology, 26
P. Wachsberger, R. Burd, C. Cardi, M. Thakur, C. Daskalakis, J. Holash, G. Yancopoulos, A. Dicker (2007)
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.International journal of radiation oncology, biology, physics, 67 5
Yutaka Takahashi, Y. Kitadai, C. Bucana, K. Cleary, L. Ellis (1995)
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.Cancer research, 55 18
N. Colombo, G. Mangili, S. Mammoliti, M. Kalling, B. Tholander, L. Sternås, G. Buzenet, D. Chamberlain (2012)
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.Gynecologic oncology, 125 1
CFG Pericay, M Saunders, A Thomas (2012)
Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM): abstract O-0024Ann Oncol, 23
P. Tang, S. Cohen, C. Kollmannsberger, G. Bjarnason, K. Virik, M. Mackenzie, L. Lourenco, Lisa Wang, A. Chen, M. Moore (2012)
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal CancerClinical Cancer Research, 18
F. Kuhnowski, C. Thieblemont, F. Jardin, F. Broussais-Guillemot, M. Meignan, J. Cabeçadas, P. Gaulard, H. Tilly, C. Oprea, C. Haioun (2010)
A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma.Journal of Clinical Oncology, 28
G. Freyer, N. Isambert, B. You, S. Zanetta, C. Falandry, L. Favier, V. Trillet‐Lenoir, S. Assadourian, K. Soussan-Lazard, S. Ziti-Ljajic, P. Fumoleau (2012)
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumoursBritish Journal of Cancer, 107
Jianzhong Huang, Jason Frischer, Anna Serur, Angela Kadenhe, A. Yokoi, K. McCrudden, T. New, K. O'toole, S. Zabski, J. Rudge, J. Holash, G. Yancopoulos, D. Yamashiro, J. Kandel (2003)
Regression of established tumors and metastases by potent vascular endothelial growth factor blockadeProceedings of the National Academy of Sciences of the United States of America, 100
I. Díaz-Padilla, L. Siu, M. Pedro-Salcedo, A. Razak, A. Colevas, F. Shepherd, N. Leighl, J. Neal, A. Thibault, L. Liu, J. Lisano, B. Gao, EB Lawson, HA Wakelee (2012)
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumoursBritish Journal of Cancer, 107
Kristina Cook, W. Figg (2010)
Angiogenesis Inhibitors: Current Strategies and Future ProspectsCA: A Cancer Journal for Clinicians, 60
H. Mackay, Ronald Buckanovich, H. Hirte, R. Correa, Paul Hoskins, J. Biagi, Lainie Martin, Gini Fleming, Robert Morgan, Lihua Wang, R. Polintan, A. Oza (2012)
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.Gynecologic oncology, 125 1
A. Patnaik, M. Pipas, L. Rosen, L. Wood, K. Phipps, M. Mulay, C. Garay, M. Korc, J. Sarantopoulos (2008)
A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary resultsJournal of Clinical Oncology, 26
T. Tonini, F. Rossi, P. Claudio (2003)
Molecular basis of angiogenesis and cancerOncogene, 22
James Williams, D. Cartland, J. Rudge, S. Egginton (2006)
VEGF Trap Abolishes Shear Stress‐ and Overload‐Dependent Angiogenesis in Skeletal MuscleMicrocirculation, 13
A. Byrne, Leorah Ross, J. Holash, Mikiye Nakanishi, Limin Hu, J. Hofmann, G. Yancopoulos, R. Jaffe (2003)
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 15
J. Bennouna, J. Sastre, D. Arnold, P. Österlund, R. Greil, E. Cutsem, R. Moos, J. Viéitez, O. Bouché, C. Borg, C. Steffens, V. Alonso-Orduña, C. Schlichting, I. Reyes-Rivera, B. Bendahmane, T. André, S. Kubicka (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.The Lancet. Oncology, 14 1
C. Abrahams, Baosheng Li, A. Parveen, G. Thurston (2010)
Abstract 5427: Combination of aflibercept (VEGF trap) and docetaxel produces increased antitumor effects associated with enhanced changes to tumor vasculatureCancer Research, 70
W. Tew, M. Gordon, J. Murren, J. Dupont, S. Pezzulli, C. Aghajanian, P. Sabbatini, D. Mendelson, L. Schwartz, S. Gettinger, A. Psyrri, J. Cedarbaum, D. Spriggs (2009)
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid TumorsClinical Cancer Research, 16
Rare Cancers Ther (2013) 1:3–19 DOI 10.1007/s40487-013-0002-8 REVIEW Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Mohamed E. Salem Sherif M. El-Refai To view enhanced content go to www.rarecancers-open.com Received: July 23, 2013 / Published online: October 16, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Methods: A search of PubMed and MEDLINE ABSTRACT from January 2000 to August 2013 was Background: Vascular endothelial growth performed using the following terms (or factor (VEGF) and related pathway elements combination of terms): VEGF, colorectal are critically important in the pathogenesis, cancer, mCRC, aflibercept, ziv-aflibercept. growth, and development of solid tumors. Studies were limited to those published in Inhibiting the VEGF signaling pathway is English. being investigated as a therapeutic strategy for Results: Phase 1 and 2 clinical trials of cancer, either by blockade of VEGF ligand aflibercept in advanced non-hematological binding or inhibition of the VEGF receptor. cancer showed acceptable safety and provided Aflibercept is a VEGF inhibitor that has been justification for further investigation. Four approved by the US Food and Drug phase 3 clinical trials were conducted to Administration for the treatment of macular evaluate aflibercept for
Oncology and Therapy – Springer Journals
Published: Oct 16, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.